MicroRNAs in Cancer

Hamed Mirzaei; Neda Rahimian; Hamid Reza Mirzaei; Javid Sadri Nahand; Michael R. Hamblin

doi:10.1007/978-3-031-79177-2_2

MicroRNAs in Cancer

Hamed Mirzaei
, Neda Rahimian
, Hamid Reza Mirzaei
, Javid Sadri Nahand
, Michael R. Hamblin

Laser Research Centre

Kashan University of Medical Sciences and Health Services
Iran University of Medical Sciences
Tehran University of Medical Sciences
Tabriz University of Medical Sciences

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

14 Citations (Scopus)

Abstract

The dysrégulation of microRNAs in cancer was first reported in 2002, when a cluster of two microRNAs (miR16 and miR-15) was detected at chromosome 13_q14.3, which had been proposed as one of the commonly eliminated genetic regions in chronic lymphocytic leukemia (CLL) patients [1]. The deletion of this miRNA cluster acts (at least partly) by increasing the expression level of the specific target of miR-15/16, which is the anti-apoptotic protein B cell lymphoma 2 (BCL2). It has been found that micro-RNAs can contribute to each cancer hallmark described by Hanahan and Weinberg [2], as well affecting the clinical progression of many cancers at different stages.

Original language	English
Title of host publication	Synthesis Lectures on Biomedical Engineering
Publisher	Springer Nature
Pages	11-40
Number of pages	30
DOIs	https://doi.org/10.1007/978-3-031-79177-2_2
Publication status	Published - 2022

Publication series

Name	Synthesis Lectures on Biomedical Engineering
ISSN (Print)	1930-0328
ISSN (Electronic)	1930-0336

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Biotechnology
Bioengineering
Biochemistry
Biomedical Engineering

Access to Document

10.1007/978-3-031-79177-2_2

Cite this

@inbook{c4698fd5a3954f81867aa93041e1d9db,

title = "MicroRNAs in Cancer",

abstract = "The dysr{\'e}gulation of microRNAs in cancer was first reported in 2002, when a cluster of two microRNAs (miR16 and miR-15) was detected at chromosome 13q14.3, which had been proposed as one of the commonly eliminated genetic regions in chronic lymphocytic leukemia (CLL) patients [1]. The deletion of this miRNA cluster acts (at least partly) by increasing the expression level of the specific target of miR-15/16, which is the anti-apoptotic protein B cell lymphoma 2 (BCL2). It has been found that micro-RNAs can contribute to each cancer hallmark described by Hanahan and Weinberg [2], as well affecting the clinical progression of many cancers at different stages.",

author = "Hamed Mirzaei and Neda Rahimian and Mirzaei, \{Hamid Reza\} and Nahand, \{Javid Sadri\} and Hamblin, \{Michael R.\}",

note = "Publisher Copyright: {\textcopyright} 2022, Springer Nature Switzerland AG.",

year = "2022",

doi = "10.1007/978-3-031-79177-2\_2",

language = "English",

series = "Synthesis Lectures on Biomedical Engineering",

publisher = "Springer Nature",

pages = "11--40",

booktitle = "Synthesis Lectures on Biomedical Engineering",

address = "United States",

}

TY - CHAP

T1 - MicroRNAs in Cancer

AU - Mirzaei, Hamed

AU - Rahimian, Neda

AU - Mirzaei, Hamid Reza

AU - Nahand, Javid Sadri

AU - Hamblin, Michael R.

PY - 2022

Y1 - 2022

N2 - The dysrégulation of microRNAs in cancer was first reported in 2002, when a cluster of two microRNAs (miR16 and miR-15) was detected at chromosome 13q14.3, which had been proposed as one of the commonly eliminated genetic regions in chronic lymphocytic leukemia (CLL) patients [1]. The deletion of this miRNA cluster acts (at least partly) by increasing the expression level of the specific target of miR-15/16, which is the anti-apoptotic protein B cell lymphoma 2 (BCL2). It has been found that micro-RNAs can contribute to each cancer hallmark described by Hanahan and Weinberg [2], as well affecting the clinical progression of many cancers at different stages.

AB - The dysrégulation of microRNAs in cancer was first reported in 2002, when a cluster of two microRNAs (miR16 and miR-15) was detected at chromosome 13q14.3, which had been proposed as one of the commonly eliminated genetic regions in chronic lymphocytic leukemia (CLL) patients [1]. The deletion of this miRNA cluster acts (at least partly) by increasing the expression level of the specific target of miR-15/16, which is the anti-apoptotic protein B cell lymphoma 2 (BCL2). It has been found that micro-RNAs can contribute to each cancer hallmark described by Hanahan and Weinberg [2], as well affecting the clinical progression of many cancers at different stages.

UR - https://www.scopus.com/pages/publications/85139433984

U2 - 10.1007/978-3-031-79177-2_2

DO - 10.1007/978-3-031-79177-2_2

M3 - Chapter

AN - SCOPUS:85139433984

T3 - Synthesis Lectures on Biomedical Engineering

SP - 11

EP - 40

BT - Synthesis Lectures on Biomedical Engineering

PB - Springer Nature

ER -

MicroRNAs in Cancer

Abstract

Publication series

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this